Who
C. Frank Bennett
EVP, Chief Scientific Officer
Company insider
Files Form 4 as: EVP, Chief Scientific Officer, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 441
- Buys
- 0
- Sells
- 86
- Bought
- $0
- Sold
- $56.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2006
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $5,644110 at $51.31 | filing |
| 31 Aug 2026filed 2 Sep 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | $5,644110 at $51.31 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $463K5,536 at $83.58 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —15,000 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.3M15,000 at $85.46 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code J | —15,000 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code J | —15,000 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $463K5,536 at $83.58 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —15,000 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.3M15,000 at $85.46 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $537K16,463 at $32.60 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $3.0M48,626 at $60.89 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5.7M71,600 at $79.10 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,463 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —48,626 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.0M12,687 at $79.88 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $65K802 at $80.76 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,463 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —48,626 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $537K16,463 at $32.60 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name C. Frank Bennett; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.